No Detail Found!

Mechanism of bevacizumab regulating jak2/stat3 pathway to inhibit angiogenesis in mice with ovarian cancer

Author(s)
C.Y. Zhang Department of Gynaecology, Jingzhou Maternal and Child Health Hospital, Jingzhou 434020, Hubei, China;
Z.E. Zhang Gynecology Second Ward, Jingzhou Central Hospital & Jingzhou Hospital, Yangtze University, Jingzhou 434020, China.
S.R. Zhang Gynecology Second Ward, Jingzhou Central Hospital & Jingzhou Hospital, Yangtze University, Jingzhou 434020, China.
Abstract
This study aimed to demonstrate the mechanism of bevacizumab in inhibiting angiogenesis in mice with ovarian cancer (OC) by regulating JAK2/STAT3 pathway. Forty healthy female BALB/C nude mice were randomly assigned to control, model, erlotinib, and bevacizumab groups. Control group received no treatment. Model group received subcutaneous injection in the left axillary region to establish the OC model and received an equal volume of normal saline. Bevacizumab group underwent the same model - establishment procedure and then received 5mg/kg bevacizumab intervention. Erlotinib group also underwent model establishment and received 30 mg/kg erlotinib intervention. Tumor tissue mass and tumor inhibition rate were recorded. The tumor pathological changes were analyzed by hematoxylineosin (HE) staining. The microvessel density (MVD) and vascular endothelial growth factor (VEGF) protein expression in tumor tissues were subjected to detection by immunohistochemistry. The expression of JAK2, STAT3, and VEGF in tumor tissues was analyzed using RT-qPCR and western blotting. Compared with the model group, tumor volume and weight of OC in erlotinib group and bevacizumab group of mice were visibly reduced. MVD, JAK2, STAT3, and VEGF in model, erlotinib, and bevacizumab groups of mice were increased versus control, while those were decreased in erlotinib and bevacizumab groups of mice versus model group (P < 0.05). Bevacizumab effectively suppressing tumor growth by reducing tumor angiogenesis and reducing the expression of key molecules of JAK2/STAT3 pathway in mice.
Publication Details
Page(s) 227-236
Published Journal: Journal of Animal and Plant sciences, Volume: 36, Issue: 1, Year: 2026

Request the full text from PASTIC

Keywords
JAK2/STAT3 pathway, Ovarian Cancer, Bevacizumab, tumor angiogenesis
0

Citations

0

Downloads

21

Views